134069-68-4
中文名称 | 134069-68-4 |
---|---|
中文同义词 | 化合物 T13107 |
英文名称 | TDN 345 |
英文同义词 | TDN 345;1-Oxa-3,8-diazaspiro[4.5]decan-2-one, 8-[4,4-bis(4-fluorophenyl)butyl]-3-(1,1-dimethylethyl)-4-methylene-;TDN345,TDN-345 |
CAS号 | 134069-68-4 |
分子式 | C28H34F2N2O2 |
分子量 | 468.58 |
EINECS号 | |
相关类别 | |
Mol文件 | 134069-68-4.mol |
结构式 |
134069-68-4 性质
沸点 | 556.2±60.0 °C(Predicted) |
---|---|
密度 | 1.18±0.1 g/cm3(Predicted) |
储存条件 | Store at -20°C |
溶解度 | 溶于二甲基亚砜 |
酸度系数(pKa) | 9.67±0.20(Predicted) |
TDN-345 (10 μM) significantly increases the intracellular NGF content in the time-course study. TDN-345 induces NGF synthesis/secretion at the concentrations of 0.1 μM; statistically significant at 1 μM. The ED 50 is 0.88 μM.
TDN-345 (0.1-1.0 mg/kg, p.o.) dose-dependently decreases the mortality and ischemic neurological deficit score when administered orally twice, 60 min before ischemia and 90 min after recirculation. Additionally, TDN-345 (0.2 or 1.0 mg/kg, p.o. once daily for 3 weeks after the onset of stroke) decreases the mortality and recurrence of stroke in SHRSP.